KROS

A month has gone by since the last earnings report for Keros Therapeutics, Inc. (KROS). Shares have added about 8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Keros Therapeutics due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Keros Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late. Keros reported a second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. The reported loss widened 91% from 76 cents per share reported in the year-ago quarter. Keros recorded no revenues, down 100% from $18.2 million a year earlier. Keros does not have a marketed product and therefore lacks a regular source of revenues. The company periodically records service and other revenues as well as license revenues, making quarterly comparisons dependent on the timing of collaboration-related revenue recognition. Service and other revenues were nil in the reported quarter compared with $18.2 million in the prior-year period. License revenues were also nil in both periods. Research and development expenses declined 48.7% year over year to $22.3 million. The decrease primarily reflected the transfer of elritercept-related development costs to Takeda and the corporate restructuring completed in 2025. General and administrative expenses fell 40.6% year over year to $8.6 million. The decrease was due to lower professional fees and reduced compensation costs tied to the 2025 restructuring. Cash and cash equivalents totaled $257.6 million as of June 30, 2026, down from $281.5 million as of March 31, 2026. Based on current operating assumptions, Keros expects its cash resources to fund operating expenses and capital expenditure requirements into the first half of 2028. The runway supports the ongoing development of rinvatercept as the company advances its clinical programs, with no recurring product revenues. In the past month, investors have witnessed a flat trend in fresh estimates. The consensus estimate has shifted 22.12% due to these changes. At this time, Keros Therapeutics has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the fifth quintile for value investors. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Keros Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Keros Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Viking Therapeutics, Inc. (VKTX), a stock from the same industry, has gained 2.2%. The company reported its results for the quarter ended June 2026 more than a month ago. Viking Therapeutics reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$1.10 for the same period compares with -$0.58 a year ago. For the current quarter, Viking Therapeutics is expected to post a loss of $1.00 per share, indicating a change of -23.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.9% over the last 30 days. Viking Therapeutics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Keros Therapeutics, Inc. (KROS) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Keros Therapeutics KROS reported second-quarter 2026 loss of $1.45 per share, wider than the Zacks Consensus Estimate of a loss of $1.25. The reported loss widened 91% from 76 cents per share reported in the year-ago quarter. Keros recorded no revenues, down 100% from $18.2 million a year earlier and in line with the Zacks Consensus Estimate. Keros does not have a marketed product and therefore lacks a regular source of revenues. The company periodically records service and other revenues as well as license revenues, making quarterly comparisons dependent on the timing of collaboration-related revenue recognition. Service and other revenues were nil in the reported quarter compared with $18.2 million in the prior-year period. License revenues were also nil in both periods. Year to date, Keros shares have plunged 50.3% against the industry’s 2% growth. Image Source: Zacks Investment Research Research and development expenses declined 48.7% year over year to $22.3 million. The decrease primarily reflected the transfer of elritercept-related development costs to Takeda and the corporate restructuring completed in 2025. General and administrative expenses fell 40.6% year over year to $8.6 million. The decrease was due to lower professional fees and reduced compensation costs tied to the 2025 restructuring. Cash and cash equivalents totaled $257.6 million as of June 30, 2026, down from $281.5 million as of March 31, 2026. Based on current operating assumptions, Keros expects its cash resources to fund operating expenses and capital expenditure requirements into the first half of 2028. The runway supports the ongoing development of rinvatercept as the company advances its clinical programs, with no recurring product revenues. Keros initiated a phase II clinical study evaluating its lead candidate, rinvatercept, in patients with Duchenne muscular dystrophy (DMD). The milestone followed a phase I study in healthy volunteers in which the candidate demonstrated increases in muscle mass and bone mineral density, alongside a reduction in fat mass. KROS continues to expect initial data from the phase II DMD study in the first half of 2027. Rinvatercept is also being developed for amyotrophic lateral sclerosis. The company plans to engage with regulatory authorities soon to discuss the design of a phase II study evaluating rinvatercept for this additional indication. Keros’ most advanced candidate, elritercept, is in late-stage development for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Takeda holds exclusive rights to develop, manufacture and commercialize the candidate worldwide outside mainland China, Hong Kong and Macau. Keros Therapeutics, Inc. price-consensus-eps-surprise-chart | Keros Therapeutics, Inc. Quote Keros currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY, Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.30, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have lost 4.9% year to date. Harmony Biosciences’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 25.16%. Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 10.2% year to date. Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%. Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 143.1% year to date. Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Keros Therapeutics, Inc. (KROS) : Free Stock Analysis Report Repligen Corporation (RGEN) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2026. “We are excited to have initiated our Phase 2 clinical trial evaluating the treatment of rinvatercept in patients with Duchenne muscular dystrophy (“DMD”), marking an important milestone in the development of our program,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “In our Phase 1 clinical trial in healthy volunteers, rinvatercept demonstrated robust pharmacological activity observed through increases in muscle mass and bone mineral density, alongside a decrease in fat mass. We look forward to the progression of the Phase 2 clinical trial, and continue to expect to present initial data in the first half of 2027.” Second Quarter 2026 Financial Results Keros reported a net loss of $28.7 million in the second quarter of 2026 as compared to a net loss of $30.7 million in the second quarter of 2025. The decrease of $2.0 million was primarily due to revenue recognized in 2025 related to Keros' license agreement with Takeda and decreased research and development efforts. Research and development expenses were $22.3 million for the second quarter of 2026 as compared to $43.5 million for the same period in 2025. The decrease of $21.2 million was primarily due to the transition of elritercept-related research and development expenses to Takeda and the corporate restructuring that was completed in 2025. General and administrative expenses were $8.6 million for the second quarter of 2026 as compared to $14.5 million for the same period in 2025. The decrease of $5.9 million was primarily due to a decrease in professional fees and a decrease in compensation costs in connection with the 2025 corporate restructuring. Keros’ cash and cash equivalents as of June 30, 2026 was $257.6 million compared to $287.4 million as of December 31, 2025. Based on current operating assumptions, Keros expects that its cash and cash equivalents as of June 30, 2026 will enable Keros to fund its operating expenses and capital expenditure requirements into the first half of 2028. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “continue”, “expect”, “plan”, “look forward to”, “will”, “potential” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for rinvatercept; and Keros’ expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact: Justin [email protected] 617-221-6042

Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +54.50%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $1.38 per share when it actually produced earnings of $1.81, delivering a surprise of +31.16%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Incyte, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.67 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 14.71%. This compares to year-ago revenues of $1.22 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Incyte shares have added about 20.4% since the beginning of the year versus the S&P 500's gain of 8.3%. While Incyte has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Incyte was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.04 on $1.47 billion in revenues for the coming quarter and $7.87 on $5.73 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Keros Therapeutics, Inc. (KROS), has yet to report results for the quarter ended June 2026. This company is expected to post quarterly loss of $1.25 per share in its upcoming report, which represents a year-over-year change of -64.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Keros Therapeutics, Inc.'s revenues are expected to be $0.35 million, down 98.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Incyte Corporation (INCY) : Free Stock Analysis Report Keros Therapeutics, Inc. (KROS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

As you might know, Keros Therapeutics, Inc. (NASDAQ:KROS) last week released its latest first-quarter, and things did not turn out so great for shareholders. It was not a great result overall, as revenues of US$367k fell 78% short of analyst expectations. Unsurprisingly, statutory losses ended up being18% larger than the analysts expected, at US$1.21 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Following the recent earnings report, the consensus from seven analysts covering Keros Therapeutics is for revenues of US$3.96m in 2026. This implies a disturbing 88% decline in revenue compared to the last 12 months. Per-share losses are expected to explode, reaching US$6.36 per share. Before this earnings announcement, the analysts had been modelling revenues of US$3.13m and losses of US$5.34 per share in 2026. So there's been quite a change-up of views after the recent consensus updates, with the analysts significantly increasing their revenue forecasts while also expecting losses per share to increase. It looks like the top line growth will not be achieved without incremental costs. Check out our latest analysis for Keros Therapeutics It will come as no surprise that expanding losses caused the consensus price target to fall 7.8% to US$21.20with the analysts implicitly ranking ongoing losses as a greater concern than growing revenues. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Keros Therapeutics at US$30.00 per share, while the most bearish prices it at US$16.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Keros Therapeutics' past performance and to peers in the same industry. We would highlight that revenue is expected to reverse, with a forecast 94% annualised decline to the end of 2026. That is a notable change from historical growth of 72% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 22% per year. It's pretty clear that Keros Therapeutics' revenues are expected to perform substantially worse than the wider industry. The most important thing to take away is that the analysts increased their loss per share estimates for next year. They also upgraded their revenue estimates for next year, even though it is expected to grow slower than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Keros Therapeutics' future valuation. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Keros Therapeutics going out to 2028, and you can see them free on our platform here. Plus, you should also learn about the 2 warning signs we've spotted with Keros Therapeutics . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026. “Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “In addition, we are excited that our partner, Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment of anemia in myelofibrosis, broadening the indication opportunity beyond myelodysplastic syndromes.” First Quarter 2026 Financial Results Keros reported a net loss of $23.7 million in the first quarter of 2026 as compared to a net income of $148.5 million in the first quarter of 2025. The decrease of $172.2 million was largely due to revenue recognized in 2025 related to Keros' license agreement with Takeda and decreased research and development efforts. Research and development expenses were $16.1 million for the first quarter of 2026 as compared to $48.7 million for the same period in 2025. The decrease of $32.6 million was primarily due to the transition of elritercept-related research and development expenses to Takeda and the corporate restructuring that was completed in 2025. General and administrative expenses were $10.1 million for the first quarter of 2026 as compared to $10.5 million for the same period in 2025. The decrease of $0.4 million was primarily due to a decrease in compensation costs in connection with the 2025 corporate restructuring. Keros’ cash and cash equivalents as of March 31, 2026 was $281.5 million compared to $287.4 million as of December 31, 2025. Based on current operating assumptions, Keros expects that its cash and cash equivalents as of March 31, 2026 will enable Keros to fund its operating expenses and capital expenditure requirements into the first half of 2028. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “continue”, “expect”, “plan”, “look forward to”, “will”, “potential” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for rinvatercept and elritercept; Takeda’s plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment of anemia in myelofibrosis; and Keros’ expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K, filed with the SEC on March 4, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact: Justin Frantz [email protected] 617-221-6042

A month has gone by since the last earnings report for Keros Therapeutics, Inc. (KROS). Shares have added about 2.5% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Keros Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers. Keros Q4 Loss Narrower Than Expected The company reported a loss per share of 86 cents per share in the fourth quarter, wider than the Zacks Consensus Estimate of a loss of 49 cents, but narrower than the loss of $1.14 per share in the year-ago quarter. Revenues of $0.4 million were down 87% year over year from $3.0 million in the year-ago quarter. The figure reflected $0.4 million of service and other revenues, primarily related to transition services under the Takeda arrangement, with no license revenues recognized in the period. This compares to license revenues of $3.0 million in the year-ago quarter. Quarter In Detail R&D expense of $17.9 million was down 61% year over year following the transition of elritercept development responsibilities and expenses to Takeda. G&A expense of $11.7 million was up 10% year over year. Cash and cash equivalents of $287.4 million as of Dec. 31, 2025, were down 49% year over year from $559.9 million. The year-over-year decline primarily reflects capital return actions in 2025, including an issuer tender offer of approximately $194.4 million and separate repurchases totaling approximately $180.6 million. Shares outstanding fell to 19.5 million at year-end. Management indicated that the cash balance is expected to fund planned operating expenses and capital expenditures into the first half of 2028, contingent on current operating assumptions. Pipeline Updates The company expects to commence a phase II study of rinvatercept in DMD in the second quarter of 2026 and plans to engage regulators on the design of a phase II study in amyotrophic lateral sclerosis (ALS) in the second half of 2026. In the past month, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -115% due to these changes. Currently, Keros Therapeutics has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the lowest quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Keros Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Keros Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Jazz Pharmaceuticals (JAZZ), a stock from the same industry, has gained 1.8%. The company reported its results for the quarter ended December 2025 more than a month ago. Jazz reported revenues of $1.2 billion in the last reported quarter, representing a year-over-year change of +10.1%. EPS of $6.64 for the same period compares with $6.60 a year ago. Jazz is expected to post earnings of $4.63 per share for the current quarter, representing a year-over-year change of +175.6%. Over the last 30 days, the Zacks Consensus Estimate has changed +17.9%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Jazz. Also, the stock has a VGM Score of A. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Keros Therapeutics, Inc. (KROS) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. “The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “With that foundation in place, our attention is firmly on execution – advancing rinvatercept into a Phase 2 clinical trial in patients with Duchenne muscular dystrophy (“DMD”) and engaging regulators on the design of a Phase 2 clinical trial in patients with amyotrophic lateral sclerosis (“ALS”). With a strong foundation in place, our focus remains on bringing potential meaningful benefit to patients and creating long-term value for our stockholders.” Recent Corporate Highlights: Board and leadership changes: In February 2026, Keros announced the appointment of Charles Newton to its board of directors, effective March 9, 2026. Concurrent with Mr. Newton joining Keros’ Board of Directors, Carl Gordon, Ph.D., C.F.A., will step down as a director of the Company. Esther Cho, J.D., Senior Vice President, General Counsel, was promoted to Chief Legal Officer, effective February 24, 2026. Selected Anticipated Program Milestones: Rinvatercept for the treatment of DMD and for the treatment of ALS: The Company expects to commence a Phase 2 clinical trial of rinvatercept in patients with DMD in the second quarter of 2026. The Company plans to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026. 2025 Financial Results Keros reported a net loss of $23.5 million for the fourth quarter and net income of $87.0 million for the year ended December 31, 2025, as compared to a net loss of $46.0 million for the fourth quarter and a net loss of $187.4 million for the year ended December 31, 2024. The decrease in net loss for the fourth quarter and the net income for the year was largely due to revenue related to Keros’ license agreement with Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), partially offset by research and development efforts as well as additional investments to support the achievement of Keros’ clinical and corporate goals. Research and development expenses were $17.9 million for the fourth quarter and $129.6 million for the year ended December 31, 2025, as compared to $45.6 million for the fourth quarter and $173.6 million for the year ended December 31, 2024. The decrease in research and development expenses for the fourth quarter and the year was primarily due to the transition of elritercept-related research and development expenses to Takeda. General and administrative expenses were $11.7 million for the fourth quarter and $46.8 million for the year ended December 31, 2025, as compared to $10.7 million for the fourth quarter and $40.8 million for the year ended December 31, 2024. The increase in general and administrative expenses for the year was primarily due to an increase in external expenses, partially offset by a decrease in compensation costs, including stock-based compensation costs, in connection with a reduction in headcount. Keros’ cash and cash equivalents as of December 31, 2025 was $287.4 million compared to $559.9 million as of December 31, 2024. The decrease in cash and cash equivalents for the year was primarily driven by Keros’ share repurchase with certain stockholders and cash tender offer. Based on current operating assumptions, Keros expects that its cash and cash equivalents as of December 31, 2025 will enable the Company to fund its planned operating expenses and capital expenditure requirements into the first half of 2028. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of ALS. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,” “potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for rinvatercept, including its regulatory plans; and Keros’ expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 5, 2025, and its other documents subsequently filed with or furnished to the SEC, including the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact: Justin Frantz [email protected] 617-221-6042 Media Contact: Mahmoud Siddig / Adam Pollack / Brooks Hussey Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

TG Therapeutics’ TGTX shares rose nearly 7% in after-hours trading, following the release of preliminary fourth-quarter and full-year 2025 results on Jan. 13, which beat expectations. TGTX issued bullish guidance for 2026 and outlined some key anticipated milestones related to Briumvi label expansion studies and other pipeline candidates. TG Therapeutics’ top line primarily comprises product sales from Briumvi, along with royalty and other revenues. Briumvi is approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). Over the past year, TG Therapeutics shares have declined 7.7% against the industry’s growth of 18.7%. Image Source: Zacks Investment Research TG Therapeutics expects total global revenues of approximately $616 million for full-year 2025, exceeding the guidance of $600 million, provided with the third-quarter 2025 earnings release in November. The preliminary sales number also beat the Zacks Consensus Estimate of $604 million. Briumvi U.S. net product revenues are expected to be approximately $182 million for the fourth quarter of 2025. For full-year 2025, Briumvi net product sales are expected to be around $594 million in the United States, surpassing the company’s November guidance of around $585 million. TG Therapeutics expects worldwide total revenues in the range of $875 million to $900 million in 2026, including net product revenues of approximately $825 million to $850 million from Briumvi sales in the United States. The 2026 guidance range indicates potential double-digit year-over-year growth compared with the expected 2025 numbers. TGTX expects operating expenses of around $350 million for the full year 2026. In 2026, TGTX expects to advance several key milestones across its development pipeline. It recently completed patient enrollment in the phase III ENHANCE study which is evaluating the potential to consolidate the day one and day 15 infusions of Briumvi into a single 600-mg infusion on day one. TG Therapeutics plans to announce pivotal topline data from the ENHANCE study in mid-year 2026. TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi for RMS in a pivotal phase III study. A self-injectable version of Briumvi could allow patients to administer doses themselves at their convenience, lowering the need for visits to medical centers for intravenous infusion. Pivotal topline data from the subcutaneous Briumvi (ublituximab) program are expected to be announced in late 2026 or the first quarter of 2027. Besides Briumvi, TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis. Preliminary phase I data from the azer-cel study is expected to be announced in the second half of 2026. TGTX currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech sector are MannKind MNKD, Keros Therapeutics KROS, and Amicus Therapeutics FOLD, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. Shares of MNKD have declined 7.1% over the past year. MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter with the average surprise being 33.33%. Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.65 to $3.47. KROS shares have risen 87.1% over the past year. Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 9098.63%. Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 54.3% over the past year. Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average earnings surprise being 20.21%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MannKind Corporation (MNKD) : Free Stock Analysis Report Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Keros Therapeutics, Inc. (KROS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company’s previously announced $375 million capital return program. Based on the final count by Computershare Trust Company, N.A., the depositary for the Tender Offer (the “Depositary”), a total of 17,712,262 shares of Keros common stock were validly tendered and not validly withdrawn, which includes shares that were tendered through notice of guaranteed delivery. In accordance with the terms and conditions of the Tender Offer, the Company accepted for purchase a total of 10,950,165 shares, for an aggregate purchase price of approximately $194.4 million, excluding fees and expenses related to the Tender Offer. Because more than 10,950,165 shares were tendered in the Tender Offer, shares were accepted for purchase on a pro rata basis, except for conditional tenders that will automatically be regarded as withdrawn if the condition was not satisfied. Keros has been informed by the Depositary that the final proration factor for the Tender Offer is approximately 62.30%. The shares purchased represent approximately 35.91% of Keros’ outstanding common stock as of November 18, 2025. The Depositary will promptly pay for all shares accepted for purchase pursuant to the Tender Offer using the Company’s existing cash and cash equivalents and return all other shares tendered and not purchased. Stockholders with questions about the Tender Offer may contact MacKenzie Partners, Inc., the information agent for the Tender Offer, toll-free at (800) 322-2885, at (212) 929-5500 or in writing at 7 Penn Plaza, New York, NY 10001. Stockholders may also contact Goldman Sachs & Co. LLC, the dealer manager for the Tender Offer, at (212) 902-8556. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,” “intention,” “potential” and “will” or similar expressions are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: developments or changes in economic or market conditions; developments or changes in the securities markets, developments or changes in Keros’ business, financial condition or cash flows, and other risks detailed in Keros’ reports filed with the Securities and Exchange Commission (the “SEC”), including its quarterly report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 5, 2025, and its other documents subsequently filed with or furnished to the SEC. Keros disclaims any intent or obligation to update these forward-looking statements. Contacts Investor Contact: Justin Frantz [email protected] 617-221-6042 Media Contact: Mahmoud Siddig / Adam Pollack / Brooks Hussey Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

LEXINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the preliminary results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company’s previously announced $375 million capital return program. Based on the preliminary count by Computershare Trust Company, N.A., the depositary for the Tender Offer (the “Depositary”), a total of approximately 16,659,732 shares of Keros common stock were validly tendered and not validly withdrawn. Additionally, approximately 1,186,829 shares were tendered through notice of guaranteed delivery. In accordance with the terms and conditions of the Tender Offer and based on the preliminary count by the Depositary, Keros expects to accept for payment an aggregate of 10,950,165 shares of its common stock, at a purchase price of $17.75 per share, for an aggregate purchase price of approximately $194.4 million, excluding fees and expenses relating to the Tender Offer. Because more than 10,950,165 shares were tendered in the Tender Offer, Keros expects to accept shares for purchase on a pro rata basis, except for conditional tenders that will automatically be regarded as withdrawn if the condition of the tender has not been met. The shares to be acquired pursuant to the Tender Offer represent approximately 35.91% of Keros’ outstanding common stock as of November 18, 2025. The number of shares expected to be purchased in the Tender Offer is preliminary and subject to change. The preliminary information contained in this press release is subject to confirmation by the Depositary and is based on the assumption that all shares tendered through notice of guaranteed delivery will be delivered within the one business day settlement period. The final number of shares to be purchased in the Tender Offer will be announced following the expiration of the guaranteed delivery period and the completion by the Depositary of the confirmation process. Payment for the shares accepted for purchase pursuant to the Tender Offer, and the return of all other shares tendered and not purchased, will occur promptly thereafter. Payment for shares will be made in cash, without interest. Stockholders with questions about the Tender Offer may contact MacKenzie Partners, Inc., the information agent for the Tender Offer, toll-free at (800) 322-2885, at (212) 929-5500 or in writing at 7 Penn Plaza, New York, NY 10001. Stockholders may also contact Goldman Sachs & Co. LLC, the dealer manager for the Tender Offer, at (212) 902-8556. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,” “intention,” “potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: the number of shares to be purchased (including the number of shares tendered through notice of guaranteed delivery) and the aggregate purchase price of shares expected to be purchased in the Tender Offer. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the final number of shares to be purchased in the Tender Offer, developments or changes in economic or market conditions; developments or changes in the securities markets, developments or changes in Keros’ business, financial condition or cash flows, and other risks detailed in Keros’ reports filed with the Securities and Exchange Commission (the “SEC”), including its quarterly report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 5, 2025, and its other documents subsequently filed with or furnished to the SEC. Keros disclaims any intent or obligation to update these forward-looking statements. Contacts Investor Contact: Justin Frantz [email protected] 617-221-6042 Media Contact: Mahmoud Siddig / Adam Pollack / Brooks Hussey Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

Keros Therapeutics, Inc. (NASDAQ:KROS) defied analyst predictions to release its quarterly results, which were ahead of market expectations. The results were impressive, with revenues of US$14m exceeding analyst forecasts by 238%, and statutory losses of US$0.18 were likewise much smaller than the analysts had forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Taking into account the latest results, the current consensus, from the eleven analysts covering Keros Therapeutics, is for revenues of US$20.2m in 2026. This implies a stressful 92% reduction in Keros Therapeutics' revenue over the past 12 months. Earnings are expected to tip over into lossmaking territory, with the analysts forecasting statutory losses of -US$3.93 per share in 2026. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$18.8m and losses of US$4.21 per share in 2026. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for both revenues and losses per share. View our latest analysis for Keros Therapeutics There was no major change to the consensus price target of US$23.63, perhaps suggesting that the analysts remain concerned about ongoing losses despite the improved earnings and revenue outlook. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Keros Therapeutics analyst has a price target of US$35.00 per share, while the most pessimistic values it at US$16.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Keros Therapeutics' past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 87% by the end of 2026. This indicates a significant reduction from annual growth of 84% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 21% annually for the foreseeable future. It's pretty clear that Keros Therapeutics' revenues are expected to perform substantially worse than the wider industry. The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that in mind, we wouldn't be too quick to come to a conclusion on Keros Therapeutics. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Keros Therapeutics analysts - going out to 2027, and you can see them free on our platform here. We don't want to rain on the parade too much, but we did also find 1 warning sign for Keros Therapeutics that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.